Second Holloway Summit Showcases Intense Search for FTD Biomarkers
Scientists have identified potential fluid and imaging markers that could discriminate between the two main proteopathies of FTD, tau and TDP-43.
587 RESULTS
Sort By:
Scientists have identified potential fluid and imaging markers that could discriminate between the two main proteopathies of FTD, tau and TDP-43.
Proteins in human blood flag organ-specific accelerated aging and disease risk. For cognition, 49 proteins better predicted decline then did plasma p-tau 181.
Each associates with distinct AD risk variants, brain atrophy, and disease severity.
C2N’s PrecivityAD2 and ALZpath Inc.’s p-tau217 immunoassay identify people with AD with good accuracy.
For a diagnostic test, specificity and sensitivity fall a little shy. Using two cut points might solve the problem.
This clarification comes after geriatricians argued that diagnosing AD in people without symptoms is premature, and the NIH pulled its name.
Across several studies, black/African Americans and Hispanic or Latino people had lower amyloid positivity rates than whites. Scientists are studying why.
Most participants in AD research studies and trials are non-Hispanic whites. At a conference in St. Louis, scientists discussed strategies to include diverse populations.
CMS has lifted restrictions that allowed beneficiaries one scan per lifetime as part of a clinical study. Approval of immunotherapies was a key factor.
A consortium of pharma companies mined data from 50,000 people in the U.K. Biobank to turn up thousands of new gene-protein connections.
DOPA decarboxylase in blood or CSF, and damaged mitochondrial DNA in blood cells, separated cases from controls.
A curated panel of 48 proteins foretold cognitive decline. It also illuminated biological pathways involved in Alzheimer's disease.
Compared to AD, tau tangles in PART accumulated slowly, and only in the medial temporal lobe. Cognition slipped subtly, and no amyloid amassed over three years.
Experts say the low specificity of Quest Diagnostics’ plasma Aβ test could lead to more false than true positives, causing distress and confusion.
Scientists at AAIC debated discrepant results, updated a model of the biomarker-efficacy relationship, and debuted the CenTauR scale for tau PET.